Isoflavones Archives - Revista Brasileira de Ginecologia e Obstetrícia

  • Artigos Originais

    Effect of ipriflavone on Wistar rats and their litters

    Revista Brasileira de Ginecologia e Obstetrícia. 2012;34(1):22-27

    Summary

    Artigos Originais

    Effect of ipriflavone on Wistar rats and their litters

    Revista Brasileira de Ginecologia e Obstetrícia. 2012;34(1):22-27

    DOI 10.1590/S0100-72032012000100005

    Views10

    PURPOSE: Evaluate the effects of ipriflavone during fetogenesis, since no studies have been conducted to assess its effect during this period. METHODS: 60 pregnant rats were divided randomly into four groups (n=15). G-control (1 mL of distilled water) and three groups treated intragastrically with ipriflavone from the 16th to the 20th post coitus (PC) day: G-300 (300 mg/kg), G-1,500 (1,500 mg/kg) and G-3,000 (3,000 mg/kg). The animals were weighed, anaesthetized intraperitoneally with xylazine and ketamine at doses of 180 mg/kg and 10 mg/kg, respectively, and sacrificed by total exsanguination on the 21st day. A complete blood count was performed and serum cholesterol, triglycerides, AST, ALT, urea, creatinine, and glucose were determined in pregnant rats. After laparotomy, the liver, kidneys, adrenals, spleen and ovaries were removed and weighed; fetuses and placentas were also weighed to obtain the average weight of the litters. Four fetuses (two males and two females) were chosen at random for the determination of the length and weight of brain, liver, kidneys and lungs. Statistical analysis: ANOVA followed by Dunnett's test. For raw data without normal distribution and homoscedasticity, we used the Kruskal-Wallis test followed by the Mann-Whitney test. Proportions were analyzed by the χ² test (p<0.05). RESULTS: Triglyceride levels (mg/dL) were: Control-G (138.8±21.8), G-300 (211.2±63.9) G-1,500 (251.5±65.2) G-3,000 (217.7±49.6); p<0.05. The body weight of fetuses (g) was: G-Control (male 3.3±0.3; female 3.1±0.3), G-300 (male 3.4±0.2; female 3.1±0.4), G-1,500 (male 3.5±0.3; female 3.2±0.3), G-3,000 (male 3.4±0.5; female 3.1±0.4). CONCLUSION: Ipriflavone did not cause maternal toxicity, but increased triglyceride levels and reduced hematocrit at higher doses. The body and organ weights of the fetuses did not change with dam treatment. There were no external malformations or fetal deaths.

    See more
    This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Artigos Originais

    Effects of high doses of genistein on mammary gland of female rat

    Revista Brasileira de Ginecologia e Obstetrícia. 2011;33(9):264-269

    Summary

    Artigos Originais

    Effects of high doses of genistein on mammary gland of female rat

    Revista Brasileira de Ginecologia e Obstetrícia. 2011;33(9):264-269

    DOI 10.1590/S0100-72032011000900008

    Views14

    PURPOSE: to evaluate the effects of high doses of genistein on the mammary glands of adult female rats. METHODS: Twenty-eight days after oophorectomy, 50 adult female rats were divided into five groups, as follows: a control group (Ctrl), three rats that received genistein (GEN) at the doses of 46 mg/kg (GEN46;), 125 mg/kg (GEN125) and 250 mg/kg (GEN250); one group received conjugated equine estrogen at the dose of 50 µg/g (ECE50). The substances were administered daily for 30 consecutive days by gavage and in the last week of the period of treatment, colpocytological exams were carried out for seven consecutive days. After treatment, the animals were anesthetized, blood samples were collected for estradiol and progesterone determination and the first pair of inguinal mammary glands was removed and processed for histomorphometric analysis. Collected data were subjected to analysis of variance supplemented by the Tukey-Kramer test (p<0.05). RESULTS: the ctrl group and the ones treated with different doses of GEN showed atrophic mammary glands, whereas the glands were more developed in the ECE group, where numerous mammary ducts and alveoli were observed. Morphometry showed a larger area of mammary parenchyma in the ECE group (98.870.1±550.4 µm²* per mm²; p<0.05) compared with other groups (Ctrl=36.875.6±443.4; GEN46=37.001.7±557.4; GEN125=36.480.8±658.3 and GEN250=37.502.8±669.3). The same occurred in the number of alveoli in the ECE group (33.2±6.9* per mm²; p<0.05) compared to the other groups (Ctrl=10.4±2.1, GEN46=11.2±3.1; GEN125=11.6±2.1 and GEN250=12.3±2.3). The estradiol level was higher in the ECE group compared to the other groups (9.4±1.7 pg/mL; p<0.05), whereas serum levels of progesterone were similar in all groups. CONCLUSION: the administration of genistein at high doses had no trophic effect on the mammary glands of rats.

    See more
    This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Effects of high doses of genistein on mammary gland of female rat
  • Artigos Originais

    Effects of soy-derived isoflavone on hot flushes and endometrial thickness: a randomized, double-blind controlled trial

    Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(10):532-537

    Summary

    Artigos Originais

    Effects of soy-derived isoflavone on hot flushes and endometrial thickness: a randomized, double-blind controlled trial

    Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(10):532-537

    DOI 10.1590/S0100-72032007001000007

    Views6

    PURPOSE: to determine the effects of soy-derived isoflavone on hot flashes, menopausal symptoms, and endometrial thickness in postmenopausal women. METHODS: this double-blind, placebo-controlled, randomized study involved 90 postmenopausal patients aged 45-60 years old attended at the Outpatient Menopause Clinic. All patients had been experiencing hot flashes accompanied or not by other hypo-estrogenic symptoms. Patients were randomized to receive either two soy capsules containing 50 mg of soy-derived isoflavone or two identical placebo capsules, twice a day for 12 weeks in a double-blind fashion. Each patient was observed for 12 weeks, with two evaluations being made, one at baseline and the other at the end of the study. At each time point, the patients were given a diary to record the severity of the climacteric symptoms experienced, assessed with a modified Kupperman index, using a 100 mm Visual Analogue Scale (VAS). The intensity of hot flashes was also assessed separately. The patients were also submitted to a transvaginal echography for the measurement of endometrial thickness. Yates chi2, ANOVA or t de Student and Mann-Whitney were used for statistical analysis. RESULTS: no significant difference was detected in the Kupperman index (64 versus 82, p>0,05) or in the hot flashes (20 versus 20, p>0,05) between the isoflavone and placebo groups. No significant difference was either detected concerning the Kupperman index and hot flashes before and after treatment, when the two groups were analyzed separately. No difference was detected in the endometrial thickness either in the isoflavone or the placebo group (0.28 versus 0.26 mm, respectively, p>0.05). CONCLUSIONS: our results indicate that 100 mg of isoflavone are not more effective than placebo in reducing hot flashes and hypo-estrogenic symptoms in postmenopausal women and present no effect on the endometrium thickness.

    See more
    This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Artigos Originais

    Effects of isoflavones on the adult rat myometrium

    Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(4):227-231

    Summary

    Artigos Originais

    Effects of isoflavones on the adult rat myometrium

    Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(4):227-231

    DOI 10.1590/S0100-72032006000400004

    Views10

    PURPOSE: to evaluate histomorphometric changes in the rat myometrium upon treatment with isoflavones, as compared with estrogens, using histological and morphometric techniques. METHODS: twenty-eight oophorectomized adult rats were randomly divided into four treatment groups: GPropi = propylene glycol (control); GExtr10 - 10 mg/kg soybean extract; GExtr300 - 300 mg/kg soy bean extract; GCee - 200 µg/kg conjugated equine estrogens (Cee). Drugs or drug vehicle were administered by gavage once a day for 21 days. Upon sacrifice, the uteri were removed and weighed. Fragments of uterine horns were collected and fixed in 10% formaldehyde and processed for paraffin inclusion. The histological sections were stained by hematoxylin and eosin and evaluated microscopically by means of an image analyzer to quantify the myometrial thickness and the number of blood vessels and eosinophils. The data were studied by analysis of variance (ANOVA) followed by the Tukey-Kramer multiple comparison test. RESULTS: isoflavones in the concentration of 300 mg/kg induced a significant increase in the myometrium thickness (GExtr300=25.6±5.0 mm) compared to control (GPropi=5.5±0.5 mm). The effect of this high dose is similar to the estrogen effect (GCee=27.5±7.9 mm). In low doses (10 mg/kg), the effect was similar to control. Isoflavones (GExtr300) induced also an increase in the number of blood vessels (GPropi=3.5±1.6; GExtr300=10.2±3.6 vessels/mm²) and of eosinophils (CPropi=0.15±0.01; GExtr300=4.3±0.9 eosinophils/mm²). These effects were comparable to those produced by Cee treatment in GCee (9.2±1.1 eosinophils/mm²). CONCLUSION: a high-dose treatment with isoflavones (300 mg/kg per day, 21 days) elicited an estrogen-like, highly significant proliferative action on the rat myometrium.

    See more
    This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Effects of isoflavones on the adult rat myometrium
  • Artigos Originais

    Placebo-controlled clinical trial with soy isoflavones for depressive symptoms in climacteric women

    Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(2):91-100

    Summary

    Artigos Originais

    Placebo-controlled clinical trial with soy isoflavones for depressive symptoms in climacteric women

    Revista Brasileira de Ginecologia e Obstetrícia. 2006;28(2):91-100

    DOI 10.1590/S0100-72032006000200004

    Views11

    PURPOSE: to evaluate the efficacy of the use of isoflavones in the treatment of depressive symptoms in climacteric women. METHODS: placebo-controlled, randomized double-blind experimental study with 84 climacteric women who were assisted at the Lauro Wanderley University Hospital Ambulatory, in João Pessoa, Paraíba, Brazil. In the evaluation of the depressive symptoms the Self-evaluation questionnare of Hamilton's rating scale for depresion (QAEH-D) was used in the pretreatment visit (VT1), and in the 8th (VT2) and 16th (VT3) week after treatment. The experimental group (GExp) received soy extract with isoflavones, 120 mg per day, and the control group (GCont), placebo. The comparison of the scores of the QAEH-D between the VT1, VT2 and VT3 groups constituted the primary measure of efficacy (t test, p<0.05). Secondary analysis included the estimate of the "domino hypothesis" and the clinical and laboratory evaluation of side effects. RESULTS: there was a significant reduction of the QAEH-D scores in the GExp (VT20.05). From VT1 to VT3, there was a significant difference (8.9%) in the reduction of the scores between GExp and GCont (p=0.03). There was no correlation between the reduction of the depressive symptoms and alterations of the vasomotor symptoms (p>0.05). There was a reduction of FSH concentrations only in GExp (p=0.02), without estradiol modifications. Side effects were not clinically relevant. CONCLUSIONS: the effect of soy isoflavones was superior to the placebo, however, of small magnitude and only identified after 8 weeks of treatment. This small effect attributed to the experimental treatment, of good tolerability, may benefit patients who have side effects due to estradiol, or those who prefer not to use hormones.

    See more
    This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Placebo-controlled clinical trial with soy isoflavones for depressive symptoms in climacteric women

Search

Search in:

Article type
Article type
abstract
book-review
brief-report
case-report
correction
editorial
letter
other
rapid-communication
research-article
review-article
Section
Section
Arigos Originais
Article
Artigo de Revisão
Original Articles
Carta ao Editor
Carta ao Editor
Cartas
Case Report
Case Reports
Caso e Tratamento
Clinical Consensus Recommendation
Corrigendum
Editoriais
Editorial
Equipamentos e Métodos
Errata
Erratas
Erratum
FEBRASGO POSITION STATEMENT
Febrasgo Statement
Febrasgo Statement Position
FIGO Statement
GUIDELINES
Integrative Review
Letter to Editor
Letter to the Editor
Métodos e Técnicas
Nota do Editor
Nota Prévia
Original Article
Original Article/Contraception
Original Article/Infertility
Original Article/Obstetrics
Original Article/Oncology
Original Article/Sexual Violence/Pediatric and Adolescent Gynecology
Original Article/Teaching and Training
Original Articles
Relato de Caso
Relato de Casos
Relatos de Casos
Reply to the Letter to the Editor
Resposta dos Autores
Resumo De Tese
Resumos de Tese
Resumos de Teses
Resumos dos Trabalhos Premiados no 50º Congresso Brasileiro de Ginecologia e Obstetrícia
Review
Review Article
Review Articles
Revisão
Short Communication
Special Article
Systematic Review
Técnica e Equipamentos
Técnicas e Equipamentos
Técnicas e Métodos
Trabalhos Originais
Year / Volume
Year / Volume
2024; v.46
2023; v.45
2022; v.44
2021; v.43
2020; v.42
2019; v.41
2018; v.40
2017; v.39
2016; v.38
2015; v.37
2014; v.36
2013; v.35
2012; v.34
2011; v.33
2010; v.32
2009; v.31
2008; v.30
2007; v.29
2006; v.28
2005; v.27
2004; v.26
2003; v.25
2002; v.24
2001; v.23
2000; v.22
1999; v.21
1998; v.20
ISSUE
ISSUE